Dorzolamide 2%, timolol 0.5% and latanoprost 0.005% are widely used in the medical management of glaucoma in humans and pets. In this study, we wanted to evaluate the effect of these three molecules belonging to different hypotensive families on intraocular pressure (IOP) and anterior segment architecture in clinically healthy cats and compare these data with those obtained in a previous study under the same conditions in healthy dogs. In this prospective study 45 cats were included and divided into 3 homogeneous groups. For 7 days eye drops were instilled in the right eye (treated eye), dorzolamide 2% BID for the first group, timolol 0.5% BID for the second group and latanoprost 0.005% SID for the third group. The left (untreated) eye of all these cats constitute a control group useful for the statistical analysis of the data. On D0 and D7, the IOP was measured with Tonovet® and then, a high frequency ultrasound (ultrasound biomicroscopy UBM) was undertaken under general anesthesia. A biostatistical study of the 1440 data was then performed. Statistical test validated the use of the controlateral eye as a control, and the representativeness of a sample of 15 animals per group. At D7, the IOP of healthy cats treated with dorzolamide 2% BID decreased significantly whereas no variation was obtained with instillation of timolol 0.5% and latanoprost 0.005%. According to our protocol, these three hypotensive molecules do not significantly affect the architecture of the anterior segment of the clinically healthy feline eye as in dogs.